Abstract
Coronary artery disease (CAD) as a major cardiovascular disease is the leading global cause of mortality, Klotho/FGF23 axis involved in development of cardiovascular disease, while the function and underlying mechanism of Klotho/FGF23 axis in CAD is unclear. Blood samples from 67 CAD patients with coronary artery bypass graft (CABG) surgery were collected, and the level of Klotho and FGF23 of those patients was measured by using an ELISA kit. Cardiomyocyte was isolated from 0 to 3 days Sprague Dawley (SD) rats. Expression of Klotho, FGF23 and the cardiomyocyte marker α-sarcomeric actin (α-SA), myosin heavy chain (MHC) and cardiac troponin I (cTnI) was assessed by immunofluorescence staining. Expression of Klotho and FGF23 mRNA was detected by qRT-PCR. Apoptosis and cell cycle were measured by flow cytometry. Cell viability was detected by using CCK-8. The protein expression of ERK/MAPK pathway related protein and cytokines production was measured by western blotting. The levels of Klotho in CAD patients increased after CABG surgery, while FGF23 decreased. Isolated cardiomyocyte morphology and structure were completed, and with stabilized beating within culture for 15 days, besides, α-SA, MHC, and cTnI proved positive. After transfected Lenti-Klotho and Lenti-FGF23 into isolated cardiomyocyte, fluorescence staining showed that the transfection was successful, and qRT-PCR results showed that the expression levels of Klotho and FGF23 mRNA significant increased compared with NEG (empty vector) group. Immunofluorescence staining results showed that compared with NEG group, there was a higher Klotho positive rate and lower FGF23 positive rate in Klotho overexpression (Klotho) group, while, there was a higher FGF23 positive rate and lower Klotho positive rate in FGF23 overexpression (FGF23) group. In addition, the expression of p-ERK1/2 and p-P38 increased in Klotho group but decreased in FGF23 group. Furthermore, overexpression of Klotho inhibited cardiomyocyte apoptosis, increased S phase fraction, promoted proliferation and elevated expression of transforming growth factor β1 (TGF-β1), nuclear factor-kappa B (NF-κB), angiotensin-II (AT-II), and activator protein-1 (AP-1), overexpression of FGF23 showed the opposite effect, however, ERK agonist (TPA) and inhibitor (U0126) reversed the effect caused by overexpression of Klotho and FGF23 separately. Klotho/FGF23 axis play a critical role in CAD progression through regulating ERK/MAPK pathway in Cardiomyocyte.
Similar content being viewed by others
Data availability
The author confirms that all data generated or analysed during this study are included in this published article.
References
Malakar, A. K., Choudhury, D., Halder, B., Paul, P., Uddin, A., & Chakraborty, S. (2019). A review on coronary artery disease, its risk factors, and therapeutics. Journal of Cellular Physiology, 234(10), 16812–16823.
Geng, H., Chen, L., Su, Y., Xu, Q., Fan, M., Huang, R., Li, X., Lu, X., & Pan, M. (2022). miR-431–5p regulates apoptosis of cardiomyocytes after acute myocardial infarction via targeting selenoprotein T. Physiological Research, 71(1), 55–62.
Jia, L., Yang, L., Tian, Y., Yang, L., Wu, D., Zhang, H., Li, M., & Wu, N. (2022). Nrf2 participates in the protective effect of exogenous mitochondria against mitochondrial dysfunction in myocardial ischaemic and hypoxic injury. Cellular Signalling., 92, 11026.
AlBadri, A., Wei, J., Quesada, O., Mehta, P. K., Xiao, Y., Ko, Y. A., Anderson, R. D., Petersen, J., Azarbal, B., Samuels, B., Henry, T. D., Cook-Wiens, G., Handberg, E. M., Van Eyk, J., Pepine, C. J., & Bairey Merz, C. N. (2020). Coronary vascular function and cardiomyocyte injury: a report from the WISE-CVD. Arteriosclerosis, Thrombosis, and Vascular Biology, 40(12), 3015–3021.
Olejnik, A., Franczak, A., Krzywonos-Zawadzka, A., Kałużna-Oleksy, M., & Bil-Lula, I. (2018). The biological role of klotho protein in the development of cardiovascular diseases. BioMed Research International. https://doi.org/10.1155/2018/5171945
Chen, K., Wang, S., Sun, Q. W., Zhang, B., Ullah, M., & Sun, Z. (2021). Klotho deficiency causes heart aging via impairing the Nrf2-GR pathway. Circulation Research, 128(4), 492–507.
Göçer, K., Aykan, A., Kılınç, M., & Göçer, N. S. (2020). Association of serum FGF-23, klotho, fetuin-A, osteopontin, osteoprotegerin and hs-CRP levels with coronary artery disease. Scandinavian Journal of Clinical and Laboratory Investigation, 80(4), 277–281.
Lu, X., & Hu, M. C. (2017). Klotho/FGF23 axis in chronic kidney disease and cardiovascular disease. Kidney Diseases (Basel, Switzerland), 3(1), 15–23.
Faul, C., Amaral, A. P., Oskouei, B., Hu, M. C., Sloan, A., Isakova, T., Gutiérrez, O. M., Aguillon-Prada, R., Lincoln, J., Hare, J. M., Mundel, P., Morales, A., Scialla, J., Fischer, M., Soliman, E. Z., Chen, J., Go, A. S., Rosas, S. E., Nessel, L., et al. (2011). FGF23 induces left ventricular hypertrophy. The Journal of Clinical Investigation, 121(11), 4393–4408.
Jia, Z., Li, Y., Zou, H., Liu, Q., Li, H., Wang, H., Chen, Z., Meng, F., & Xing, Z. (2021). The effect of extracorporeal circulation assisted coronary artery bypass grafting on Klotho-FGF23 axis and the expression of vascular growth factor. Chinese Journal of Cardiovascular Research., 19(12), 1108–1114.
Hess, J., Angel, P., & Schorpp-Kistner, M. (2004). AP-1 subunits: quarrel and harmony among siblings. Journal of Cell Science, 117(Pt 25), 5965–5973.
Kadota S, Tanaka Y, Shiba Y. Heart regeneration using pluripotent stem cells. (2020).Journal of cardiology.76(5):459–463.
Sridharan, D., Pracha, N., Rana, S. J., Ahmed, S., Dewani, A. J., Alvi, S. B., Mergaye, M., Ahmed, U., & Khan, M. (2023). Preclinical large animal porcine models for cardiac regeneration and its clinical translation: role of hiPSC-derived cardiomyocytes. Cells, 12(7), 1090.
Wang, Q., Su, H., & Liu, J. (2022). Protective effect of natural medicinal plants on cardiomyocyte injury in heart failure: targeting the dysregulation of mitochondrial homeostasis and mitophagy. Oxidative Medicine and Cellular Longevity, 2022, 1–24.
van Venrooij, N. A., Pereira, R. C., Tintut, Y., Fishbein, M. C., Tumber, N., Demer, L. L., Salusky, I. B., & Wesseling-Perry, K. (2014). FGF23 protein expression in coronary arteries is associated with impaired kidney function. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association., 29(8), 1525–1532.
Kuro-o M. Klotho. (2010).Pflugers Archiv : European Journal of Physiology, 459(2), 333–343.
Prié, D. (2021). FGF23 and cardiovascular risk. Annales d’Endocrinologie, 82(3–4), 141–143.
Böckmann, I., Lischka, J., Richter, B., Deppe, J., Rahn, A., Fischer, D. C., Heineke, J., Haffner, D., & Leifheit-Nestler, M. (2019). FGF23-mediated activation of local RAAS promotes cardiac hypertrophy and fibrosis. International Journal of Molecular Sciences, 20(18), 4634.
Xue, M., Yang, F., Le, Y., Yang, Y., Wang, B., Jia, Y., Zheng, Z., & Xue, Y. (2021). Klotho protects against diabetic kidney disease via AMPK- and ERK-mediated autophagy. Acta Diabetologica, 58(10), 1413–1423.
Zhang, R., Song, B., Hong, X., Shen, Z., Sui, L., & Wang, S. (2020). microRNA-9 inhibits vulnerable plaque formation and vascular remodeling via suppression of the SDC2-Dependent FAK/ERK signaling pathway in mice with atherosclerosis. Frontiers in Physiology, 11, 804.
Sun, L. F., An, D. Q., Niyazi, G. L., Ma, W. H., Xu, Z. W., & Xie, Y. (2018). Effects of Tianxiangdan Granule treatment on atherosclerosis via NF-κB and p38 MAPK signaling pathways. Molecular Medicine Reports, 17(1), 1642–1650.
Corsetti, G., Pasini, E., Scarabelli, T. M., Romano, C., Agrawal, P. R., Chen-Scarabelli, C., Knight, R., Saravolatz, L., Narula, J., Ferrari-Vivaldi, M., Flati, V., Assanelli, D., & Dioguardi, F. S. (2016). Decreased expression of Klotho in cardiac atria biopsy samples from patients at higher risk of atherosclerotic cardiovascular disease. Journal of Geriatric Cardiology : JGC, 13(8), 701–711.
Hansson, G. K. (2017). Inflammation and atherosclerosis: The end of a controversy. Circulation, 136(20), 1875–1877.
Nolte M, Margadant C. Controlling Immunity and Inflammation through Integrin-Dependent Regulation of TGF-β. (2020).Trends in cell biology.30(1):49–59.
McCaffrey, T. A. (2009). TGF-beta signaling in atherosclerosis and restenosis. Frontiers in bioscience (Scholar edition)., 1, 236–245.
Mitchell, J. P., & Carmody, R. J. (2018). NF-κB and the transcriptional control of inflammation. International Review of Cell and Molecular Biology, 335, 41–84.
Karunakaran, D., Nguyen, M. A., Geoffrion, M., Vreeken, D., Lister, Z., Cheng, H. S., Otte, N., Essebier, P., Wyatt, H., Kandiah, J. W., Jung, R., Alenghat, F. J., Mompeon, A., Lee, R., Pan, C., Gordon, E., Rasheed, A., Lusis, A. J., Liu, P., et al. (2021). RIPK1 expression associates with inflammation in early atherosclerosis in humans and can be therapeutically silenced to reduce NF-κB activation and atherogenesis in mice. Circulation, 143(2), 163–177.
Zhou, L., Ma, B., & Han, X. (2016). The role of autophagy in angiotensin II-induced pathological cardiac hypertrophy. Journal of Molecular Endocrinology., 57(4), R143–R152.
Dandona, P., Dhindsa, S., Ghanim, H., & Chaudhuri, A. (2007). Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade. Journal of Human Hypertension, 21(1), 20–27.
Zhao, Q., Wirka, R., Nguyen, T., Nagao, M., Cheng, P., Miller, C. L., Kim, J. B., Pjanic, M., & Quertermous, T. (2019). TCF21 and AP-1 interact through epigenetic modifications to regulate coronary artery disease gene expression. Genome Medicine, 11(1), 23.
Miao, G. H., Yang, L. X., Qi, F., Wang, X. M., Shi, Y. K., & Li, M. Q. (2008). The role of activator protein-1 in unstable coronary atherosclerotic changes. Zhonghua Nei Ke Za Zhi, 47(7), 545–547.
Acknowledgements
This work was supported in part by the Funds of Yunnan Fundamental Research Projects (Nos. 202201AT070277, and 202102AA310003-12); Advanced Health Technical Project of Yunnan Province (Nos. 202305AD160059 and H-2018028); Health Science and Technology Project of Kunming (Nos. 2022-SW-011, 2020-SW-005, and 2020-SW-009).
Funding
This article was funded by Funds of Yunnan Fundamental Research Projects, Nos. 202201AT070277, and 202102AA310003-12, Advanced Health Technical Project of Yunnan Province, Nos. 202305AD160059 and H-2018028, Health Science and Technology Project of Kunming, Nos. 2022-SW-011.
Author information
Authors and Affiliations
Contributions
Zheng Jia, Zhengjiang Xing and Li Zhao contributed to the conception and design, writing and critical revision of the article. Qian Liu, Ying Xie, and Jie Wei contributed to data collection and interpretation. Fandi Meng, Bin Zhao, Zhenkun Yu, analysis.
Corresponding authors
Ethics declarations
Conflict of interest
No potential conflict of interest was reported by the authors.
Ethical Approval
The study was supported by the Ethics Committee of Yan'an Hospital Affiliated to Kunming Medical University (2017-008-01), and all patients provided written informed consent.
Additional information
Handling Editor: Lu Cai.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Supplementary file3 (AVI 53260 kb)
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Jia, Z., Liu, Q., Xie, Y. et al. Klotho/FGF23 Axis Regulates Cardiomyocyte Apoptosis and Cytokine Release through ERK/MAPK Pathway. Cardiovasc Toxicol 23, 317–328 (2023). https://doi.org/10.1007/s12012-023-09805-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12012-023-09805-6